person · Reporting owner

Davis Todd C

Disclosed activity across 5 companies

Tapewire entity: 32389
SEC CIK: 0001392029

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
LIGAND PHARMACEUTICALS INCLGND · Entity 3825	Director · Chief Executive Officer	June 30, 2026	July 06, 2026
PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452	Director	June 10, 2026	June 12, 2026
Pelthos Therapeutics Inc.PTHS · Entity 6798	Director	June 11, 2026	June 15, 2026
Vaxart, Inc.VXRT · Entity 6654	Director	August 04, 2022	August 08, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LIGAND PHARMACEUTICALS INC

Report date June 30, 2026 · Filed July 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	199,513	Reported balance After 2026-06-30 transaction · row 1 1 source row Row 1 · 2026-06-30 · Other · Acquired 132 · Balance 199,513 F1: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

PALVELLA THERAPEUTICS, INC.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $102.19 · Expires 2036-06-10	Direct	3,000	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 3,000 · Balance 3,000 F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date.

Pelthos Therapeutics Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	75,834	Ending reported balance After 2026-06-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-06-11 · Purchase · Acquired 35,445 · Balance 75,331 F1: This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2026-06-11 · Purchase · Acquired 503 · Balance 75,834 F2: This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Common StockSEC Table I · non-derivative	IndirectBy Ligand Pharmaceuticals Incorporated	1,500,000	Reported balance Holding disclosure · report date 2026-06-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,500,000 F3: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Vaxart, Inc.

Report date August 04, 2022 · Filed August 08, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	125,905	Reported balance After 2022-08-04 transaction · row 1 1 source row Row 1 · 2022-08-04 · Grant · Acquired 7,375 · Balance 125,905 F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-08-03	Direct	44,224	Reported balance After 2022-08-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-04 · Grant · Acquired 44,224 · Balance 44,224 F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.

F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIODELIVERY SCIENCES INTERNATIONAL INC

Report date March 22, 2022 · Filed March 22, 2022

Section 16 reporting ended · disclosed 2022-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-03-22 transaction · row 1 1 source row Row 1 · 2022-03-22 · Other · Disposed 252,207 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2022-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-03-22 · Disposition to issuer · Disposed 22,685 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.93	Direct	Reported balance After 2022-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-03-22 · Disposition to issuer · Disposed 48,123 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66	Direct	Reported balance After 2022-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-03-22 · Disposition to issuer · Disposed 85,760 · Balance 0 F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 14, 2022, by and among the Issuer, Collegium Pharmaceutical, Inc., ("Parent"), and Bristol Acquisition Company Inc., a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of Issuer, $0.001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of March 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $5.60 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: Each Issuer RSUs that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the Merger Consideration.

F4: Immediately prior to the Effective Time, each Issuer option that was outstanding and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Issuer option (any such Issuer option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding taxes, an amount in cash equal to the excess of the Merger Consideration over the per share exercise price of such In-the-Money Cash Out Option. All Issuer options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 30, 2026 Filed Jul 6, 2026 21:10 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	OtherCommon Stock	132	$160.71	$21,213.65	Disclosure SEC source: 0002001011-26-000106 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,513 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 11, 2026 Filed Jun 15, 2026 21:25 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	PurchaseCommon Stock	503	$28.73	$14,449.23	Disclosure SEC source: 0001919246-26-000088 · wk-form4_1781558723.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,834 F2 · price: This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 11, 2026 Filed Jun 15, 2026 21:25 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	PurchaseCommon Stock	35,445	$27.80	$985,534.05	Disclosure SEC source: 0001919246-26-000088 · wk-form4_1781558723.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,331 F1 · price: This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:05 UTC	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantStock Option (Right to Buy) · Derivative	3,000	$0.00 Strike: $102.19	$0.00	Disclosure SEC source: 0001104659-26-073426 · tm2617372-2_4seq1.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders following the grant date, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document
March 02, 2026 Filed Mar 28, 2026 00:33 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	50,058	$0.00 Strike: $202.55	$0.00	Disclosure SEC source: 0002001011-26-000033 · primary_doc.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,058 Underlying: Common Stock · 50,058 shares Expires 2036-03-02 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
March 02, 2026 Filed Mar 28, 2026 00:33 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	10,495	$0.00	$0.00	Disclosure SEC source: 0002001011-26-000033 · primary_doc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,381 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2027; February 15, 2028; and February 15, 2029, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Pursuant to an election under the Issuer's Nonqualified Deferred Compensation Plan, delivery of shares otherwise issuable upon each vesting date will be deferred. Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	2,805	$183.83	$515,643.15	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 7 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,886 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	4,255	$183.83	$782,196.65	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 6 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,691 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document
February 15, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	2,039	$183.83	$374,829.37	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 5 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,946 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document
February 14, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	15,600	$183.83	$2,867,748.00	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 4 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,985 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document
February 14, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	39,644	$0.00	$0.00	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 3 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,585 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document
February 14, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	8,178	$183.83	$1,503,361.74	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,941 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of PSUs. Read SEC document
February 14, 2026 Filed Feb 18, 2026 21:21 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	20,782	$0.00	$0.00	Disclosure SEC source: 0002001011-26-000011 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,119 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units ("PSUs"). Read SEC document
December 04, 2025 Filed Dec 9, 2025 00:37 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GiftCommon Stock	130	$0.00	$0.00	Disclosure SEC source: 0002001011-25-000121 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,337 F1 · price: Represents a bona fide gift of shares to a charitable entity. Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:43 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantStock Option · Derivative	58,230	Not disclosed Strike: $13.50	Not disclosed	Disclosure SEC source: 0001753926-25-001105 · ownership.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,230 Underlying: Common Stock · 58,230 shares Expires 2035-07-02 F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. Read SEC document
July 02, 2025 Filed Jul 8, 2025 01:43 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantRestricted Stock Units · Derivative	19,108	Not disclosed Strike: $13.50	Not disclosed	Disclosure SEC source: 0001753926-25-001105 · ownership.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,969 Underlying: Common Stock · 19,108 shares Expires 2035-07-02 F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years. F3 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document
July 02, 2025 Filed Apr 1, 2026 21:45 UTC Amendment	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantCommon Stock	19,108	$0.00	$0.00	Disclosure SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 3 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,886 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:02 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	OtherSeries A Convertible Preferred Stock · Derivative	31,278.681	Not disclosed Strike: $10.00	Not disclosed	Disclosure SEC source: 0001753926-25-001075 · ownership.xml · derivative · entry 4 Davis Todd C · CIK 0001392029 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,127,868 Underlying: Common Stock · 3,127,868 shares Expires not disclosed F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F4 · shares: Received in exchange for shares of LNHC, Inc. ("LNHC") common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand. F4 · price: Received in exchange for shares of LNHC, Inc. ("LNHC") common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:02 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	ConversionSeries A Convertible Preferred Stock · Derivative	15,000	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0001753926-25-001075 · ownership.xml · derivative · entry 3 Davis Todd C · CIK 0001392029 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,000 Underlying: Common Stock · 1,500,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion. F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document
July 01, 2025 Filed Jul 4, 2025 01:02 UTC	Pelthos Therapeutics Inc. PTHS · Entity 6798	ConversionCommon Stock	1,500,000	$10.00	$15,000,000.00	Disclosure SEC source: 0001753926-25-001075 · ownership.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Ligand Pharmaceuticals Incorporated Disclosed balance after: 1,500,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document
June 30, 2025 Filed Jul 2, 2025 23:31 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	OtherCommon Stock	233	$91.08	$21,221.06	Disclosure SEC source: 0002001011-25-000050 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,467 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 10, 2025 Filed Jun 11, 2025 23:59 UTC	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantNon-Qualified Stock Option (right to buy) · Derivative	12,350	$0.00 Strike: $26.23	$0.00	Disclosure SEC source: 0001583648-25-000038 · edgardoc.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,350 Underlying: Common Stock · 12,350 shares Expires 2035-06-10 Read SEC document
May 09, 2025 Filed May 14, 2025 00:05 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	PurchaseCommon Stock	5,523	$105.67	$583,629.22	Disclosure SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 3 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,234 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $105.1300 to $106.0000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 09, 2025 Filed May 14, 2025 00:05 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	PurchaseCommon Stock	2,307	$104.53	$241,149.56	Disclosure SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,711 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $104.1300 to $105.1000. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
May 09, 2025 Filed May 14, 2025 00:05 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	PurchaseCommon Stock	1,680	$104.57	$175,677.60	Disclosure SEC source: 0002001011-25-000029 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,404 Read SEC document
March 04, 2025 Filed Mar 6, 2025 23:54 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	93,476	$0.00 Strike: $115.26	$0.00	Disclosure SEC source: 0002001011-25-000014 · edgardoc.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,476 Underlying: Common Stock · 93,476 shares Expires 2035-03-04 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
March 04, 2025 Filed Mar 6, 2025 23:54 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	21,382	$0.00	$0.00	Disclosure SEC source: 0002001011-25-000014 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,724 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2026; February 15, 2027; and February 15, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:44 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	4,255	$120.00	$510,600.00	Disclosure SEC source: 0002001011-25-000013 · edgardoc.xml · nonDerivative · entry 4 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,342 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document
February 15, 2025 Filed Feb 20, 2025 01:44 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	2,231	$120.00	$267,720.00	Disclosure SEC source: 0002001011-25-000013 · edgardoc.xml · nonDerivative · entry 3 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,597 F3 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document
February 14, 2025 Filed Feb 20, 2025 01:44 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Tax withholdingCommon Stock	6,966	$120.00	$835,920.00	Disclosure SEC source: 0002001011-25-000013 · edgardoc.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,828 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of performance stock units. Read SEC document
February 14, 2025 Filed Feb 20, 2025 01:44 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	20,784	$0.00	$0.00	Disclosure SEC source: 0002001011-25-000013 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,794 F1 · price: Represents shares of common stock issued upon the vesting and certification of performance stock units (PSUs). Read SEC document
December 13, 2024 Filed Dec 18, 2024 01:44 UTC	PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452	GrantStock Option (right to buy) · Derivative	24,700	$0.00 Strike: $13.60	$0.00	Disclosure SEC source: 0001062993-24-020821 · form4.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,700 Underlying: Common Stock · 24,700 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest and become exercisable in 36 equal monthly installments through the third anniversary of the grant date. Read SEC document
November 13, 2024 Filed Nov 15, 2024 21:22 UTC	Pelthos Therapeutics Inc. CHRO · Entity 6798	GrantRestricted Stock Units · Derivative	49,605	Not disclosed Strike: $0.64	Not disclosed	Disclosure SEC source: 0001753926-24-001951 · ownership.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 263,306 Underlying: Common Stock · 49,605 shares Expires 2024-11-13 F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters. F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters. Read SEC document
November 13, 2024 Filed Apr 1, 2026 21:45 UTC Amendment	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantCommon Stock	4,961	$0.00	$0.00	Disclosure SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,778 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document
August 08, 2024 Filed Aug 9, 2024 21:52 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	PurchaseCommon Stock	2,500	$97.39	$243,480.50	Disclosure SEC source: 0002001011-24-000067 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,010 Read SEC document
June 28, 2024 Filed Jul 2, 2024 23:44 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	OtherCommon Stock	350	$60.71	$21,247.45	Disclosure SEC source: 0002001011-24-000062 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,510 F1 · kind: These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 14, 2024 Filed Jun 19, 2024 00:00 UTC	Pelthos Therapeutics Inc. CHRO · Entity 6798	GrantRestricted Stock Units · Derivative	128,977	Not disclosed Strike: $1.30	Not disclosed	Disclosure SEC source: 0001753926-24-001127 · ownership.xml · derivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,701 Underlying: Common Stock · 128,977 shares Expires 2034-06-14 F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years. Read SEC document
June 14, 2024 Filed Apr 1, 2026 21:45 UTC Amendment	Pelthos Therapeutics Inc. PTHS · Entity 6798	GrantCommon Stock	12,900	$0.00	$0.00	Disclosure SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,817 F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I. F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary. F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,156	$0.00 Strike: $68.51	$0.00	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · derivative · entry 8 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,156 shares Expires 2030-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,855	$0.00 Strike: $67.24	$0.00	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · derivative · entry 7 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,855 shares Expires 2031-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	3,556	$0.00 Strike: $66.19	$0.00	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · derivative · entry 6 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,556 shares Expires 2029-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	7,448	$0.00 Strike: $46.20	$0.00	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · derivative · entry 5 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,448 shares Expires 2032-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	3,556	$66.19	$235,371.64	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · nonDerivative · entry 4 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,156	$68.51	$147,707.56	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · nonDerivative · entry 3 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	2,855	$67.24	$191,970.20	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · nonDerivative · entry 2 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:47 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	Exercise / conversionCommon Stock	7,448	$46.20	$344,097.60	Disclosure SEC source: 0002001011-24-000035 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,593 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:49 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantEmployee Stock Option (right to buy) · Derivative	131,723	$0.00 Strike: $89.20	$0.00	Disclosure SEC source: 0002001011-24-000027 · edgardoc.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,723 Underlying: Common Stock · 131,723 shares Expires 2034-02-27 F2 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:49 UTC	LIGAND PHARMACEUTICALS INC LGND · Entity 3825	GrantCommon Stock	32,436	$0.00	$0.00	Disclosure SEC source: 0002001011-24-000027 · edgardoc.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,145 F1 · shares: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on February 15, 2025; February 15, 2026; and February 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:15 UTC	Pelthos Therapeutics Inc. CHRO · Entity 6798	ConversionSecured Convertible Promissory Note · Derivative	Not disclosed	Not disclosed Strike: $4.80	$175,000.00	Disclosure SEC source: 0001753926-24-000374 · ownership.xml · derivative · entry 2 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,167 shares Expires 2024-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share. Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:15 UTC	Pelthos Therapeutics Inc. CHRO · Entity 6798	Exercise / conversionCommon Stock	29,167	$4.80	$140,001.60	Disclosure SEC source: 0001753926-24-000374 · ownership.xml · nonDerivative · entry 1 Davis Todd C · CIK 0001392029 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share. F1 · price: Represents the face amount of $175,000 this senior secured convertible promissory note, due February 29, 2024, which automatically converted into 29,167 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering, which is $6.00 per share. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.